• Species Reactivity

  Human

• Specificity

  Detects human Kallikrein 14 in direct ELISAs.

• Source

  Monoclonal Mouse IgG    ₁ Clone # 337903

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Kallikrein 14    
  Gln19-Met248    
  Accession # AAD50773

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Immunoprecipitation

  25 µg/mL

  Conditioned cell culture medium spiked with Recombinant Human Kallikrein 14 (Catalog # ),

• 
  

• Neutralization

  Measured by its ability to neutralize Recombinant Human Kallikrein 14 (0.1 µg/mL, Catalog # ) cleavage of the fluorogenic peptide substrate Boc-VPR-AMC (100 µM, Catalog # ). The Neutralization Dose (ND    ₅₀) is typically 0.07 µg/mL.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Kallikrein 14

Human tissue kallikreins refer to a group of secreted serine proteases that are encoded by homologous genes clustering on chromosome 19q13.3-4. As a member of this family, human tissue Kallikrein 14 (hKLK14) is present in many tissues, with high levels in breast, skin, prostate, and brain. The 251 amino acid hKLK14 precursor consists of a signal peptide (residues 1 to 18), a pro peptide (residues 19 to 24) and an active protein (residues 25 to 251) (1). Its enzymatic activity has been shown to be mainly trypsin-like (2). However, its physiological substrates and functions are still unclear. Several studies have suggested that hKLK14 may have clinical utility as a biomarker for cancer of the breast, ovary, and prostate (3, 4). In addition, it may be the initiator of a kallikrein proteolytic cascade responsible for the degradation of the adhesion structures in the stratum corneum (2). The purified, secreted rhKLK14 corresponds to the pro form (residues 19 to 248) with a replacement of the last three residues with a His tag at the C-terminus. When activated by thermolysin, it displays enzymatic activity towards a fluorogenic peptide described above. This activity can be inhibited by rhSerpin A4, E1, and F2 (R&D Systems, Catalog # 1669-PI, 1786-PI, and 1470-PI, respectively).

• References:

1. Yousef, G. M. et al. (2001) Cancer Res. 61:3425.

2. Brattsand, M. et al. (2004) J. Invest. Dermatol. 124:198.

3. Borgono, C. et al. (2003) Cancer Res. 63:9032.

4. Yousef, G. M. et al. (2003) Prostate. 56:287.

• Entrez Gene IDs:

  43847 (Human)

• Alternate Names:

  EC 3.4.21; EC 3.4.21.-; hK14; Kallikrein 14; Kallikrein-like protein 6; kallikrein-related peptidase 14; KLK14; KLKL6; KLK-L6kallikrein-14